Literature DB >> 3167203

Variability of the molecular defects corresponding to the presence of a Philadelphia chromosome in human hematologic malignancies.

G Saglio1, A Guerrasio, A Tassinari, C Ponzetto, A Zaccaria, P Testoni, B Celso, G Rege Cambrin, A Serra, L Pegoraro.   

Abstract

By analyzing a total of 107 patients affected by chronic myelogenous leukemia (CML; chronic and blast crisis) or lymphoid and myeloid Philadelphia chromosome (Ph') positive acute leukemias, we have investigated the relationship between the molecular defect on the Ph' chromosome and the associated hematologic phenotype. As expected, approximately half of the Ph' positive acute leukemias showed a breakpoint on chromosome 22 falling outside the "breakpoint cluster region" (bcr) known to be involved in CML. Surprisingly, seven of 80 CML cases in chronic phase also showed rearrangements falling outside the bcr region. In two of these cases the breakpoint on chromosome 22 was mapped between 9 and 12 kb upstream to the bcr region. In another case, the breakpoint was located approximately 16 kb downstream to bcr. In the remaining four cases, the precise position of the rearrangement could not be localized with the available bcr probes. DNAs from patients with CML blast crises showed classical bcr rearrangements. No molecular changes were observed during the progression of the disease in six patients whose DNA from both a chronic and acute phase was available. Our results seem to indicate a greater degree of variability of chromosome 22 breakpoints in CML than previously observed, and the lack of additional rearrangements on the Ph' chromosome in CML blast crises with respect to chronic phase.

Entities:  

Mesh:

Year:  1988        PMID: 3167203

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  C T Denny; N P Shah; S Ogden; C Willman; T McConnell; W Crist; A Carroll; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

Review 2.  Philadelphia chromosome-positive acute myeloid leukemia with tetraploidy.

Authors:  Hiroki Yamaguchi; Koiti Inokuchi; Ena Yokomizo; Junko Miyata; Ayako Watanabe; Mituharu Inami; Kenji Tajika; Kazuo Dan
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  Further evidence for the molecular heterogeneity of chronic myeloid leukemia.

Authors:  A Hernandez; L Corral; A Muñiz; C Alaez; E Espinosa; G Martinez; P Hernandez
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

4.  Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.

Authors:  M Kelliher; A Knott; J McLaughlin; O N Witte; N Rosenberg
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

5.  Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.

Authors:  J McLaughlin; E Chianese; O N Witte
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

6.  Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia.

Authors:  A Grossman; R T Silver; Z Arlin; M Coleman; E Camposano; P Gascon; P A Benn
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

7.  Philadelphia chromosome-positive chronic myelogenous leukemia with deleted fusion of BCR and ABL genes.

Authors:  K Ohyashiki; J H Ohyashiki; H Iwabuchi; T Tauchi; A Iwabuchi; K Toyama
Journal:  Jpn J Cancer Res       Date:  1990-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.